204 related articles for article (PubMed ID: 8487077)
21. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T
No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634
[TBL] [Abstract][Full Text] [Related]
23. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2.
Bodmer S; Strommer K; Frei K; Siepl C; de Tribolet N; Heid I; Fontana A
J Immunol; 1989 Nov; 143(10):3222-9. PubMed ID: 2809198
[TBL] [Abstract][Full Text] [Related]
24. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
25. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells].
Nitta T; Ishizawa A; Ito M; Sato K; Yagita H; Kumura K
No Shinkei Geka; 1990 Nov; 18(11):1001-6. PubMed ID: 2247192
[TBL] [Abstract][Full Text] [Related]
26. GDF-15 contributes to proliferation and immune escape of malignant gliomas.
Roth P; Junker M; Tritschler I; Mittelbronn M; Dombrowski Y; Breit SN; Tabatabai G; Wick W; Weller M; Wischhusen J
Clin Cancer Res; 2010 Aug; 16(15):3851-9. PubMed ID: 20534737
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.
Kuppner MC; Hamou MF; Sawamura Y; Bodmer S; de Tribolet N
J Neurosurg; 1989 Aug; 71(2):211-7. PubMed ID: 2545842
[TBL] [Abstract][Full Text] [Related]
28. Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance.
Maxwell M; Galanopoulos T; Neville-Golden J; Antoniades HN
J Neurosurg; 1992 May; 76(5):799-804. PubMed ID: 1373442
[TBL] [Abstract][Full Text] [Related]
29. Suppression of TGF-beta1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells.
Yamanaka R; Tanaka R; Yoshida S; Saitoh T; Fujita K; Naganuma H
J Neurooncol; 1999 May; 43(1):27-34. PubMed ID: 10448868
[TBL] [Abstract][Full Text] [Related]
30. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
31. [Infiltrative and cytolytic activities of lymphokine-activated killer (LAK) cells against a human glioma mass: ultrastructural analysis using a three-dimensional multicellular spheroid model].
Iwasaki K
Nihon Geka Hokan; 1990 Jan; 59(1):39-54. PubMed ID: 2130768
[TBL] [Abstract][Full Text] [Related]
32. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells.
Zuber P; Kuppner MC; De Tribolet N
Eur J Immunol; 1988 Oct; 18(10):1623-6. PubMed ID: 3142781
[TBL] [Abstract][Full Text] [Related]
33. An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas.
Nickl-Jockschat T; Arslan F; Doerfelt A; Bogdahn U; Bosserhoff A; Hau P
Int J Oncol; 2007 Feb; 30(2):499-507. PubMed ID: 17203233
[TBL] [Abstract][Full Text] [Related]
34. [Immunomodulatory effects of interferons on target human gliosarcoma cells in the tumor-specific CTL- and LAK-mediated cytolysis].
Miyatake S; Kondou S; Aoki T; Iwasaki K; Ohyama K; Ootsuka S; Oda Y; Kikuchi H
No Shinkei Geka; 1991 Nov; 19(11):1053-9. PubMed ID: 1762655
[TBL] [Abstract][Full Text] [Related]
35. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape.
Platten M; Wick W; Weller M
Microsc Res Tech; 2001 Feb; 52(4):401-10. PubMed ID: 11170299
[TBL] [Abstract][Full Text] [Related]
36. Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells.
Tritschler I; Gramatzki D; Capper D; Mittelbronn M; Meyermann R; Saharinen J; Wick W; Keski-Oja J; Weller M
Int J Cancer; 2009 Aug; 125(3):530-40. PubMed ID: 19431147
[TBL] [Abstract][Full Text] [Related]
37. TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis.
Jennings MT; Maciunas RJ; Carver R; Bascom CC; Juneau P; Misulis K; Moses HL
Int J Cancer; 1991 Aug; 49(1):129-39. PubMed ID: 1874566
[TBL] [Abstract][Full Text] [Related]
38. TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2).
Strutz F; Zeisberg M; Renziehausen A; Raschke B; Becker V; van Kooten C; Müller G
Kidney Int; 2001 Feb; 59(2):579-92. PubMed ID: 11168939
[TBL] [Abstract][Full Text] [Related]
39. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
40. Correlation between suppression of c-myc and antiproliferative effect of transforming growth factor-beta 1 in thyroid carcinoma cell growth.
Usa T; Tsukazaki T; Namba H; Ohtsuru A; Kimura H; Villadolid MC; Nagataki S; Yamashita S
Endocrinology; 1994 Oct; 135(4):1378-84. PubMed ID: 7925100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
